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Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown cause characterized by expansion of
autoreactive lymphocytes. Regulatory T cells (Tregs) are a component of the normal immune system and contribute to the
maintenance of peripheral tolerance. Treg abnormalities have been associated with several autoimmune diseases and there
is interest in the role of Tregs in SLE. We previously demonstrated that transfer of expanded CD4
+CD25
+CD62L
HI Tregs slows
the development of lupus in (NZBxNZW)F1 (B/W) mice. However in the absence of Treg specific surface antigens, cell
purification remains a compromise between the breadth and purity of the population isolated. Importantly, purified
populations always contain Foxp3
2 effector T cells (Teffs) that theoretically could exacerbate autoimmunity in the recipient.
Here we explore the impact of transferring the more comprehensive, but less pure Treg subset defined by CD4
+CD25
+
expression on development of murine lupus. All cells were FACS sorted and expanded prior to adoptive transfer.
Development of proteinuria and survival were measured. We found that exogenous expansion of CD4
+CD25
+ cells
produced a population containing 70–85% CD4
+Foxp3
+Tregs. Expanded Tregs had higher CTLA-4 and Foxp3 expression,
increased in vitro suppression capacity, and prolonged in vivo survival as compared to freshly isolated cells. Adoptive
transfer of expanded CD4
+CD25
+ Tregs inhibited the onset of glomerulonephritis and prolonged survival in mice.
Importantly the population of Teff contained within the adoptively transferred cells had reduced survival and proliferation
capacity as compared to either co-transferred Tregs or transferred Teffs expanded in the absence of Tregs. These studies
demonstrate that adoptive transfer of expanded CD4
+CD25
+Foxp3
+Tregs has the capacity to inhibit the onset of murine
lupus and that this capacity is significant despite transfer of co-cultured Teff cells. These data indicate that when co-
expanded with regulatory T cells, exogenously activated Teffs from autoimmune patients may not pose a significant risk of
promoting disease.
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Introduction
Systemic lupus erythematosus (SLE) is a prototypic autoimmune
disease characterized by loss of tolerance to self-antigens,
expansion of autoreactive lymphocytes, and immune mediated
injury to multiple organ systems. The immunologic defects that
permit development of SLE are incompletely understood, but as
with other autoimmune diseases there is a failure to inhibit
activation and expansion of autoreactive lymphocytes that escape
central tolerance mechanisms. Natural regulatory T cells (Tregs)
are a thymically derived subset of CD4
+ lymphocytes present in
both humans and mice that serve an essential role in modulating
the function of the immune system and in maintaining peripheral
tolerance[1–4]. In vitro, CD4
+ Tregs have a strong capacity to
inhibit activation and expansion of both alloreactive and
autoreactive T cells[3,5]. In vivo, the Treg T cell receptor (TCR)
repertoire is biased towards recognition of self-antigens[6,7] and
upon activation, Tregs exert a potent capacity to inhibit
autoreactive lymphocytes[6–11]. Recognition of the important
role of Tregs in maintenance of peripheral tolerance has led to
studies demonstrating an association between abnormal Treg
function or prevalence and the development of autoimmune
disease[8,10,12,13]. In several mouse systems, studies have
demonstrated that therapies that restore or supplement Treg
function and numbers can inhibit the onset and progression of
some autoimmune diseases[8,12–16].
A number of studies have examined the relation between Tregs
and SLE. In some but not all mouse models of lupus, defects in
Treg prevalence or function have been reported [13,17,18].
Similarly, a growing number of reports have described defects in
the number and function of Tregs isolated from peripheral blood of
patients with active SLE[19–23]. These observations suggest that
Treg dysfunction may be a contributing factor in the immune
pathogenesis of SLE. We have previously demonstrated that
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exogenously activated and expanded Treg subset characterized by
CD4
+CD25
+CD62L
HI expression can inhibit the onset and rate of
progression of lupus in (NZBxNZW)F1 (B/W) mice[24]. This
study suggested the possibility that augmentation of the regulatory
T cell population and/or function in vivo might be beneficial.
However, although these cells were able to inhibit disease, the
population transferred reflected only a subset of natural Tregs in
mice with active lupus. Some evidence suggests that different Treg
subsets may have unique roles in the maintenance of peripheral
tolerance and thus transfer of a more comprehensive Treg subset
may have additional or unique therapeutic benefits[10,25–27]. In
addition, the intrinsic resistance of Tregs to exogenous expansion
and the probability that a large number of Tregs will be required to
enhance peripheral tolerance in humans makes it desirable to
isolate a larger Tregs subset for exogenous expansion. Unfortu-
nately, due to the lack of Treg specific surface antigens, purification
of a more comprehensive Treg subset increases the contamination
by the non-regulatory effector T cell (Teff) population. Despite a
growing number of published purification protocols for isolating
subsets of regulatory T cells, no approach to date has
demonstrated the capacity to isolate the entire Treg population
with 100 percent specificity. Recent studies demonstrate that even
the intracellular transcription factor Foxp3, considered the gold
standard for identification of regulatory cells, is expressed
transiently in some activated non-regulatory human T cells[28]
further highlighting the difficulty in both identifying and purifying
a comprehensive regulatory T cell population. Importantly, in
autoimmune prone mice or humans with SLE, contamination of
therapeutic Tregs by non-regulatory effector cells can include
pathologic autoreactive lymphocytes that may have potential to
exacerbate autoimmune disease if expanded and transferred back
into the donor.
In this study we isolate and expand CD4
+CD25
+ T cells from
29-week-old lupus prone B/W mice to assess the function of this
more comprehensive, but less pure Treg population. We
demonstrate that exogenously expanded CD4
+CD25
+ Tregs have
a robust in vitro suppression capacity despite the inevitable presence
of co-expanded non-regulatory Teffs, many of which are contained
in the CD4
+CD25
+CD62L
LO pool of recently activated T cells.
Utilizing adoptive transfer studies, we demonstrate that
CD4
+CD25
+Foxp3
+ Tregs continue to divide in vivo and are long
lived following adoptive transfer. Interestingly, while purified and
in vitro expanded CD4
+CD25
2Foxp3
2 Teff cells also demonstrate
the capacity to expand and survive following adoptive transfer,
contaminating CD4
+CD25
+Foxp3
2 Teff cells expanded in co-
culture with CD4
+CD25
+Foxp3
+ Tregs cells exhibit poor survival
and proliferation following adoptive transfer. Finally, we show that
exogenously expanded, adoptively transferred CD4
+CD25
+ T cells
containing a mixed population of Foxp3
+Tregsand co-expanded
Foxp3
2Teffs, to lupus prone B/W mice can enhance suppression
of autoreactive lymphocytes and delay the development of
autoimmune disease.
Materials and Methods
Mice
Six-week-old B/W mice were purchased from Jackson Labora-
tories (Bar Harbor, Maine) and housed in the AAALAC
accredited San Francisco VAMC Animal Care Facility under
the supervision of a licensed veterinarian. The VAMC Institu-
tional Animal Care Use Committee reviewed and approved all
protocols utilized in this study.
Antibodies and reagents
Monoclonal antibody (mAb) against CD4 (GK1.5), anti-Fc
(2.4G2) and anti-CD3 (2C11), were purified in our lab. The
GK1.5 mAb was FITC-conjugated. CD4 mAb (PerCp-Cy5.5
conjugated, RM4-5), CD62L (allophycocyanin(APC)-conjugated,
MEL-14), and neutralizing antibodies to IL-10 (JES5-16E3) were
purchased from BD Pharmingen (San Diego, CA). Pacific Blue-
CD4 (RM4-5), Foxp3 mAb (FITC-conjugated and APC-conju-
gated, FJK-16s), isotype control (rat IgG2a), fixation and
permeabilization buffers (catalog no. 00-5523) were purchased
from eBioscience (San Diego, CA). Biotinylated goat anti-mouse
IgG (catalog no. M30215), goat anti-mouse IgM (catalog
no. M31515), and FITC-conjugated streptavidin (SA1001) were
purchased from Caltag Laboratories (Burlingame, CA). Biotiny-
lated rat anti-mouse C3 (11H9) was purchased from HyCult
Biotechnology (The Netherlands). The anti-CD25 mAb (R-PE-
conjugated, 7D4) and anti-CTLA4 mAb (R-PE-conjugated, 1B8)
were purchased from Southern Biotechnology Associates, Inc
(Birmingham, AL). Neutralizing antibodies to TGF-b (1D11) were
purchased from R&D Systems (Minneapolis, MN). Carboxyfluor-
oscein succinimidyl ester (CFSE) and SNARF-1 carboxylic acid,
acetate, succinimidyl ester (S22801, special packaging) was
purchased from Molecular Probes/Invitrogen Life Technologies
(Carlsbad, CA).
Lymphocyte isolation
Following animal sacrifice, the spleen and cervical, axillary,
inguinal, and renal lymph nodes were harvested. Single cell
suspensions were prepared in DMEM with 2% fetal calf serum
(FCS) by passing tissue through nylon mesh. In experiments of
CFSE or SNARF-1 labeled in vivo cell survival, salivary glands,
kidneys, lung and liver were also mechanically dissociated and
lymphocytes from these tissues were isolated by ficoll gradient.
FACS analysis and cell sorting
Cell suspensions were blocked with anti-Fc mAb prior to
monoclonal antibody labeling. Lymphocytes were labeled with
PerCp-Cy5.5-CD4 or FITC-CD4, PE-CD25, APC-CD62L.
Foxp3 expression was measured utilizing an aliquot of cells
stained with PerCp-Cy5.5-CD4 that was fixed and permeabilized,
blocked with anti-Fc mAb, and stained with FITC-Foxp3 or
FITC-IgG2a isotype control per manufacturers instructions
(eBioscience, San Diego, CA). Combined expression of membrane
bound and intracellular CTLA-4 expression was measured by first
labeling surface antigen and then utilizing the fixation and
permeabilization and blocking protocol defined for Foxp3 above
to label intracellular antigen. All FACS analysis and sorting was
performed on a FACSAria (Becton Dickinson, Mountain View,
CA) instrument utilizing FACSDiva software and the purity
prioritization algorithm. Purity checks of sorted cells routinely
demonstrated greater than 98% purity.
Cell culture
Purified CD4
+CD25
+, CD4
+CD25
+CD62L
HI,
CD4
+CD25
+CD62L
LO, and CD4
+CD25
2 cells were isolated
from 28–29 week old mice by FACS sorting. The frequency of
Tregs in each sorted populations was measured by staining for
Foxp3 expression in an aliquot of sorted cells. Cells were cultured
utilizing the protocol previously described[29]. Briefly, purified
cells were maintained at a concentration of 0.721610
6 cells/ml
over an 8-day culture period in DMEM (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum (Biosource Interna-
tional, Camarillo, CA). 2,000 IU/ml rhIL-2 (Hoffmann-LaRoche,
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5 mM Hepes (Sigma-Aldrich, St. Louis, MO), NEAA, 0.5 mM
sodium pyruvate, 1 mM glutaMAX (all from Invitrogen) and
50 mM b-mercaptoethanol (Sigma-Aldrich). Cells were stimulated
with bead coupled anti-CD3 and anti-CD28 antibodies (Xcyte
beads, Xcyte Therapeutics Inc., Seattle, WA). Following expan-
sion, cells were separated from the Xcyte beads by centrifugation
in Lympholyte-M (Cedarlane Laboratories, Burlington, NC) at
230G for 25 minutes. Aliquots of expanded cells were routinely
assessed for purity by measurement of CD4
+ and Foxp3
+
expression and for suppressive function in a mixed lymphocyte
suppression assay.
Suppression assay
The CD4
+CD25
2CD62L
HI T cells were purified by FACS and
served as responder T cells (Tresp) in mixed lymphocyte
suppression assays. CD4
+ depleted splenocytes were irradiated at
2,000 rads and served as antigen presenting cells (APCs). Purified
Tresp and APCs (75,000 each) were combined in 96 well U-bottom
plates with soluble anti-CD3 at 4 mg/ml. Tregs were added to
obtain a range of Tresp:Treg ratios. Cells were cultured for 60 hours
prior to addition of 1 mCi/well of [
3H] thymidine and the assay
was then harvested 12 hours later. All assays were performed in
triplicate. Tritium incorporation was measured on a MicroBeta
Scintillation Counter (Wallac Oy, Turku Finland). The tritium
incorporation at each Tresp:Treg was divided by incorporation in
the Tresp only wells to calculate a suppression index (SI) for each
experiment.
In vivo survival of adoptively transferred Tregs and Teffs
The in vivo survival of both freshly isolated and exogenously
expanded Tregs and expanded Teffs was assessed in a series of
experiments utilizing adoptively transferred CFSE or SNARF-1
labeled cells. All adoptive transfer studies reported in this paper
utilized unmanipulated recipient mice (no irradiation or immune
depletion prior to adoptive transfer). Lymphocytes from donor
mice were FACS sorted and the frequency of Tregs and Teffs in
freshly sorted populations was measured by FACS analysis of
Foxp3 expression in an aliquot of sorted cells. Expanded cells
obtained from the 8-day expansion protocol described above were
also analyzed for Foxp3 expression to determine the ratio of Tregs
to non-regulatory Teff post-expansion. Fresh or expanded cells
were CFSE labeled, extensively washed in sterile saline, and
concentrated in 200 ml of sterile PBS in preparation for tail-vein
injection to each mouse. The survival of both freshly isolated and
exogenously expanded cells was measured at set time intervals
from 2 to 30 days following adoptive transfer. Mice were sacrificed
and single cell suspensions of lymph node and spleen were
prepared. In order to detect CFSE
+ cells that trafficked outside of
the lymphatic system, lymphocytes were also recovered from
salivary glands, kidneys, lung and liver. Recovered cells were
stained with Pacific Blue-CD4 and APC-Foxp3 mAbs prior to
FACS analysis in order to differentiate the survival and
proliferation of CFSE
+CD4
+Foxp3
+Tregs from CFSE
+CD4
+-
Foxp3
2Teffs. In these experiments, two types of CD4
+Foxp3
2Teffs
were designated based on the culture conditions from which they
were derived. The first Teff population was derived from the
CD4
+CD25
+Foxp3
2Teffs (5–10% of cells) co-isolated during
sorting for CD4
+CD25
+Foxp3
+Tregs. During cell culture, these
contaminating Teffs are co-expanded in a Treg predominant
environment and were therefore designated as ‘‘conditioned Teffs’’
(Teff-conditioned) to reflect potential conditioning of the Teff function
by Treg co-culture. A second population of Teff cells was generated
by first depleting the CD4
+CD25
+ T cells (the majority of Tregs)
prior to the in vitro expansion of for 8-days. This expanded Teff
population contained ,2% CD4
+Foxp3
+ Treg cells and was
therefore considered as ‘‘unconditioned’’ Teffs. In specified
experiments designed to assess differential survival of ‘‘uncondi-
tioned’’ Teff cells from Teff-conditioned cells following co-injection
with Tregs, mice received two tail-vein injections on the same day,
one containing expanded, SNARF-1 labeled unconditioned Teffs
and the second injection containing the expanded CFSE labeled
Tregs/Teff-conditioned cells. Mice were sacrificed 4 or 5 days after
injection and cell survival was assessed by FACS analysis of
lymphocytes recovered from lymphatic and solid organ tissue of
recipient mice (as defined above). SNARF-1
+ and CFSE
+ cells
were then FACS sorted followed by labeling with FITC-Foxp3 or
APC-Foxp3 mAbs respectively to permit differentiation of Tregs
(CFSE
+Foxp3
+), Teff-conditioned (CFSE
+Foxp3
2) cells, and ‘‘uncon-
ditioned’’ Teff (SNARF-1
+ Foxp3
2) fractions. The presence of any
SNARF-1
+ Foxp3
+ cells was also assessed.
Adoptive cell transfer to treatment study mice
All Treg and Teff cells were purified from donor B/W mice age-
matched to recipient mice. Expanded CD4
+CD25
+ Tregs (con-
taining 80–85% Foxp3
+Tregs and 15–20%Foxp3
2Teff-conditioned)
and CD4
+CD25
2Teff controls (with ,2% Tregs) were depleted of
Xcyte beads as above and extensively washed in sterile saline. A
total of 6610
6 Tregs concentrated in 200 ml of sterile PBS were
transferred by tail-vein injection to each mouse. Littermate mice
were divided into two control groups and received either an
equivalent volume of sterile PBS or 6610
6 expanded
CD4
+CD25
2 T cells in 200 ml sterile PBS. A total of two separate
cell sorts, exogenous expansion, and adoptive transfers were
preformed in order to generate sufficient cells to treat the target of
at least 20 mice per arm. The final treatment cohort contained 65
animals, comprised of 44 littermate mice divided into 15 Treg,1 5
Teff, and 14 PBS recipients and 21 littermate mice divided into 7
mice per arm, for a total of 22 Treg treated mice, 22 Teff treated
mice, and 21 PBS treated mice. All animals were 29-weeks-old at
the time of adoptive transfer.
Assessment of lupus disease activity and survival
A total of 65 mice (21–22 mice per group) were followed for the
development of renal disease as measured by proteinuria and for
survival. Proteinuria was measured using Uristix (Bayer Corp,
Elkhart, IN). Antibodies to double-stranded DNA (anti-dsDNA
Ab) were measured utilizing an ELISA previously established in
our lab[30]. In a separate experiment, cohorts of 29-week old mice
(5 per arm) received either Tregs or PBS control (as per the above
protocol) and these mice were then sacrificed 8-weeks following
adoptive transfer to provide renal histology. Fixed kidney tissue
was stained with hematoxylin and eosin for evaluation of
glomerulosclerosis and tubular damage and cryopreserved sections
of kidney tissue were stained with FITC conjugated antibodies to
IgG, IgM, and C3 for assessment of immune complex deposition
that was scored by a blinded reader using a scoring system
previously established in our laboratory[30].
Statistical analysis
Suppression assays were performed in triplicate and the mean
thymidine incorporation was assessed using the Mann-Whitney U
test. Antigen expression by mean fluorescent intensity, anti-
dsDNA Ab titers and renal histologic damage and immune
complex deposition scores were compared by Mann-Whitney U
test. Development of proteinuria, defined as $100 mg/dl on serial
testing, and survival in treatment and control cohorts were
compared by x
2 analysis using the Yates correction.
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Purification and expansion of CD4
+CD25
+T cells results in
a mixed population of Tregs and Teffs
In B/W mice with active lupus, the frequency of natural Tregs,
as measured by Foxp3
+ expression, was 9662% in the cells
identified by CD4
+CD25
+CD62L
HI expression (Figure 1A). The
CD4
+CD25
+CD62L
LO population contained both Foxp3
+Tregs
and a significant population of recently activated Foxp3
2Teff, such
that a typical sort of this quadrant produced a population
containing 85–92% Foxp3
+Tregs and 8–15% Foxp3
2 Teffs
(Figure 1A, 36-week old B/W mouse with early proteinuria). In
vitro expansion of cells over an 8-day period increased the relative
frequency of Foxp3
2 cells due to the more rapid proliferation of
Teffs as compared to Tregs during culture. The
CD4
+CD25
+CD62L
HI cells maintain this surface phenotype
during expansion and produce an expanded population that is
,85–90% Foxp3
+ post-expansion (Figure 1B). Expansion of the
CD62L
LO subset produced cells with mixed surface phenotype
(33% express CD62L
HI) and a reduced Foxp3
+ purity (65–85%)
due to the higher initial Teff prevalence (Figure 1C). On average,
culture of the entire CD4
+CD25
+ cell population produced a
population that expanded 30 to 40-fold and was 70–85%
CD4
+Foxp3
+ (Figure 1D).
In vitro Treg suppressor function is similar between
subsets of CD25
+ Tregs and this function is enhanced by
in vitro activation and expansion
We previously demonstrated that the in vitro suppressive
capacity of the CD4
+CD25
+CD62L
HI Treg fraction is not
affected by the age or disease state of donor B/W mice and is
equivalent to that of similar cells from non-autoimmune prone
BALB/c mice[24]. In this study, the CD4
+CD25
+CD62L
LO
Tregs from B/W mice with active disease were isolated by FACS
sorting and the suppressor capacity was compared to the
CD4
+CD25
+CD62L
HI Treg fraction. Freshly isolated cells
demonstrated equivalent suppression between these CD62L
HI
and CD62L
LO Treg subsets (Figure 2A, p$0.25 for each cell
ratio, 3–6 mice per group).
To evaluate the effect of ex vivo expansion on suppressive
function, we isolated the entire CD4
+CD25
+ T cell population
and measured in vitro suppressive function before and after
expansion. Despite the presence of 15–20% co-expanded Teffs,
the expanded CD4
+CD25
+Tregs demonstrated significantly
enhanced suppression capacity across the range of Tresp:Treg
ratios tested as compared to freshly isolated CD4
+CD25
+ cells
(Figure 2B, p#0.04 for each cell ratio, 6 mice per group). This
enhanced Treg suppressor function following exogenous expan-
sion is consistent with prior reports of Treg function in other
murine models and with our previous findings with the
CD4
+CD25
+CD62L
HITreg fraction in B/W mice[24,31]. Be-
cause levels of Foxp3
+ and CTLA-4 expression in Tregs have
been correlated with suppressor function of these cells and these
antigens are also known to be up-regulated by Treg activation,
we measured their expression in freshly isolated and exogenously
expanded Tregs from young and old B/W mice by FACS. Levels
of Foxp3 or CTLA-4 expression in freshly isolated Tregs as
measured by mean fluorescent intensity (MFI) did not vary with
mouse age or organ distribution (data not shown). However,
consistent with prior reports in other mouse strains[29,31] there
was a marked increase in both Foxp3
+ and CTLA-4 expression
in B/W Tregs following exogenous expansion (Figure 2C–D,
p,0.01 for both, 3–6 mice per group).
Exogenous expansion significantly enhances in vivo
survival of Tregs, but not of co-cultured Teff
We assessed the in vivo survival of freshly isolated and
exogenously expanded Tregs and expanded Teff cells in a series
of transfer experiments utilizing mixed populations of expanded
Tregs/Teff-conditioned, and Teffs. Prior studies have shown that Treg
interactions with Teffs can induce long term Teff anergy[32,33], but
whether this in vitro interaction influences the in vivo survival and
proliferation of contaminating Teffs within the expanded Treg
population is unknown. The in vivo survival of freshly isolated,
adoptively transferred CD4
+CD25
+Tregs was first compared to
that of exogenously expanded Tregs. Cohorts of 3 mice each
received aliquots of sorted fresh or expanded CFSE labeled cells,
each containing 1.6610
6 Foxp3
+ Tregs. Five days following
transfer, recipient mice were sacrificed and the lymphocyte
recovery from lymph nodes, spleen and tissues (liver, kidney,
lung, salivary glands) was measured. An aliquot of cells was then
stained for Foxp3 prior to FACS analysis. The number of
CFSE
+Foxp3
+ cells (as a percentage of all cells in the aliquot) and
the total cell recovery from each mouse was then used to estimate
the Treg survival in each mouse. As shown in Figure 3, in vivo
survival of exogenously expanded, adoptively transferred Tregs at
day 5 is significantly enhanced as compared to that of freshly
isolated cells (p,0.01). Freshly isolated, adoptively transferred
CFSE
+Tregs could no longer be consistently detected by FACS
when mice were examined 10 days post transfer.
The long-term in vivo survival of exogenously expanded Tregs
was then assessed by following 10610
6 cells for up to 30 days
following transfer (3 mouse cohort). As shown in Figure 4, a small
population of CFSE
+ positive cells could be detected at 30 days
(Figure 4A, ,0.2% of CD4
+ T cells). To ensure these rare cells
were actually the adoptively transferred CFSE labeled Tregs and
not just very large cells or cellular doublets with bright
autofluorescence, the CFSE bright population was FACS sorted
and stained for Foxp3 expression. As shown in Figure 4B, Foxp3
was detected in .90% of CFSE
+ cells consistent with long term
survival and proliferation of exogenously expanded, adoptively
transferred Treg.
To assess the survival of contaminating, co-transferred Teff cells
contained within the expanded Treg population, cohorts of 3 mice
received expanded CD4
+CD25
+ cells derived from the high purity
Treg culture that contained 85% CD4
+Foxp3
+Tregs and 15%
contaminating CD4
+Foxp3
2Teff-conditioned (Figure 5A). Two to
eight days following transfer mice were sacrificed and the lymph
node, spleen, and tissue infiltrating lymphocytes were FACS
analyzed for CFSE and Foxp3. As demonstrated in Figure 5B–C,
the frequency of CFSE
+Foxp3
2Teff-conditioned relative to CFSE
+-
Foxp3
+Tregs rapidly declined such that by day 4 the Teff-conditioned
comprised ,3% of the transferred cells (an 80% decline) with no
evidence of significant Teff-conditioned division by CFSE dilution. To
determine if this decline in Teffs prevalence was a result of
conditioning during co-culture with Tregs or an intrinsic property
of all exogenously expanded, adoptively transferred Teffs, in vivo
survival of Teffs expanded in the absence of Tregs was assessed
(‘‘unconditioned’’ Teffs generated from expansion of CD25-
depleted CD4
+ T cells. Expanded cells were 98% CD4
+Foxp3
2-
Teffs). In the first experiment, survival and division of 5610
6
transferred CFSE labeled, Foxp3
2 unconditioned Teffs could be
detected by FACS up to seventeen days post-transfer, at which
time CFSE fluorescent intensity approached the autofluorescence
baseline (Figure 6). The relative survival of unconditioned Teffs was
then compared to survival of expanded Tregs following transfer of
these two populations into the same mouse. Mice received
injections of 3.45610
6 expanded, CFSE labeled CD4
+CD25
+
Treg Treatment of Murine Lupus
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+ expression in freshly isolated and expanded CD4
+ Treg cells. A) Foxp3 expression in fresh CD25
+CD62L
HI cells (Q2, 96%)
versus CD25
+CD62L
LO cells (Q4, 89%). Isotype control antibody shown for each histogram. B) Expanded Q2 cells demonstrating maintenance of
CD62L
HI and Foxp3
+expression (90%). C) Expanded Q4 cells demonstrating up-regulation of CD62L
HI on 33% of cells and a mixture of 65%
Foxp3
+Tregs and 35% Foxp3
2 Teff cells post-expansion. D) Foxp3
+ expression (grey histogram, 85% of cells) following expansion of the entire
CD4
+CD25
+ T cell subset. Isotype control shown in black histogram.
doi:10.1371/journal.pone.0006031.g001
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+CD25
+Treg function and phenotype is enhanced by exogenous expansion. A) Freshly isolated CD62L
HI and CD62L
LO
fractions of CD4
+CD25
+Tregs demonstrate equivalent suppression capacity in vitro as measured by mixed lymphocyte suppression assay (p$0.25 for
each cell ratio, 3–6 mice per group). The Suppression Index measures the capacity of Tregs to suppress Tresp proliferation (as measured by decreased
tritium-labeled thymidine incorporation) at different Tresp:Treg ratios divided by the maximal Tresp proliferation in the absence of Tregs B) Ex vivo
expansion of CD4
+CD25
+ Tregs significantly enhances the ability of these cells to suppress proliferation of Tresp cells derived from 29-week-old B/W
mice (p#0.04 for each cell ratio, 6 mice per group). C–D) Foxp3
+ and CTLA-4 (surface and intracellular) expression in exogenously expanded Tregs
were significantly greater than in freshly isolated Tregs as measured by mean-fluorescent intensity (p=0.007, p,0.001 respectively, 3–6 mice per
group).
doi:10.1371/journal.pone.0006031.g002
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second injection of 2.86610
6 expanded, SNARF-1 labeled
CD4
+CD25
2 Teffs (‘‘unconditioned’’ Teffs). Initial ratio of injected
cells was 45% Tregs, 10% Teff-conditioned, and 45% unconditioned
Teffs. Four to five days following transfer, analysis of surviving
CFSE
+ and SNARF-1 cells demonstrated a persistence of Tregs
and Teffs, but not Teff-conditioned. Figure 7A–B show a characteristic
result at day 4 at which time approximately equal numbers of
CSFE and SNARF-1 labeled cells could be recovered from the
lymphatic system and organs (0.4% of total lymphocytes each,
ratio of sorted CFSE to SNARF-1 is 54% to 46%). Foxp3 analysis
of recovered CFSE
+ cells demonstrates that these cells are
comprised almost entirely of Tregs (Figure 7C, 97% of surviving
CFSE
+ cells are Foxp3
+Tregs, 3% Foxp3
2Teff-conditioned). Recov-
ered SNARF-1
+ were unconditioned Teffs as expected (Figure 7D,
99% Foxp3
2) (characteristic findings from 5 mice). This data is
consistent with evidence in Figures 5 and 6 demonstrating that
impaired Teff-conditioned survival is a consequence of co-culture with
Tregs and not an intrinsic characteristic of all adoptively transferred
Teffs.
Adoptive transfer of exogenously expanded CD4
+CD25
+
Tregs to pre-nephritis mice slows the progression to
proteinuria and prolongs survival
To determine if adoptive transfer of a mixed population of
exogenously expanded CD4
+CD25
+ Tregs can suppress murine
lupus, we transferred cells to a large cohort of 29 week-old B/W
mice without clinical disease. Treatment mice received 6610
6
Tregs via tail vein injection, based on our prior ability to delay
disease onset utilizing this number of CD62L
HI Tregs. Control
mice received either an equivalent number of exogenous expanded
CD4
+CD25
2 cells or PBS. Following adoptive transfer, mice in
the active treatment group had delayed progression to significant
renal disease, such that eight weeks after cell transfer, only 32% of
animals in the treatment group had developed proteinuria
compared to 59% in the CD4
+CD25
2 Teff mice and 62% in
the PBS control group (Figure 8, p,0.025 for both comparisons.
Dataset S1 contains proteinuria and survival data). Mice sacrificed
for renal pathology and immunohistochemical evaluation at 8
weeks following the initiation of therapy exhibited diminished
immune complex deposition among those that received Tregs
(Dataset S2 contains proteinuria data). Indirect immunfluores-
cence demonstrated that kidneys from Treg treated mice (Figure 9,
A–B) had less IgG and IgM immune complex deposition as
compared to control treated mice (Figure 9, C–D, p#0.05 for both
comparisons. Differences in C3 deposition and renal damage
pathologic scoring did not reach statistical significance). The
prevalence of proteinuria in Treg treated mice remained
significantly lower than either control group up to 12 weeks
following the adoptive transfer (p#0.008 for both comparisons).
Inhibition of renal disease in Treg recipients correlated with an
improved survival first evident 9 weeks following adoptive transfer
(Figure 10), p,0.05 Treg vs. either control. This survival advantage
in the Treg recipients remained significant during the 12 weeks
following transfer (p#0.026). In mice followed beyond the 12-
week experiment (15 Treg,1 5T eff, 14 PBS), it was observed that
the majority of mice in each treatment arm eventually developed
proteinuria, but the delay in disease onset and prolonged survival
of Treg recipient mice remained evident to 24 weeks following
therapy (Dataset S1). At baseline, all mice in each treatment arm
had anti-dsDNA antibody titers below the detection threshold.
Significant variability in autoantibody titer was observed among
mice in each group during follow-up and the difference between
groups did not reach statistical significance.
Discussion
In this report we expand on our prior work demonstrating the
ability of exogenously expanded, adoptively transferred Tregs to
inhibit the development of murine lupus. We demonstrate that
exogenous expansion and transfer of Tregs contained within the
population of CD4
+CD25
+ T cells suppresses the onset of
glomerulonephritis and prolongs survival in a murine model of
lupus. Importantly, the co-transfer of a population of co-purified/
co-expanded Teffs did not negate this therapeutic benefit in mice.
These results underscore the remarkable ability of Tregs to suppress
autoreactive immune responses. They also address an important
concern with respect to the therapeutic potential of this approach
in terms of the risk of simultaneous transfer of activated,
autoreactive and pathogenic Teffs to autoimmune recipients. In
this study we found that co-expanded and transferred Teff, that are
present as a consequence of sorting and expanding Tregs without
the availability of Treg specific cell surface antigens, did not off-set
the therapeutic benefit of exogenously expanded, adoptively
transferred Tregs. In addition, we tracked the survival and
proliferation of non-regulatory/Foxp3
2 cells co-transferred with
the Treg population and found Teffs expanded in the presence of
Tregs do not persist in vivo, particularly compared to transferred
Foxp3
+ Tregs. The poor survival and lack of division of the co-
cultured Foxp3
2Teffs produced under our in vitro expansion
conditions indicates these cells are unlikely to have the capacity
to contribute either to the disease suppression (as iTregs)o r
adversely to the pool of self-reactive Teffs. This observation is
consistent with the evidence that activated Tregs produce a
significant amount of TGF-b and that both human and mouse
Teffs activated in the presence of TGF-b develop an anergic
phenotype and under some conditions can be converted to an
induced suppressor cell (iTreg)[32,34,35]. This finding is an
Figure 3. Enhanced in vivo survival of expanded Tregs as
compared to freshly isolated Tregs following adoptively
transfer. Bar graph demonstrates that the number of exogenously
expanded CFSE
+CD4
+Foxp3
+Tregs recovered from lymphatic and solid
organs 5 days after adoptive transfer (adjusted for the variability in total
cell recovery from each recipient mouse) is significantly greater than
that for freshly isolated and adoptively transferred Tregs (p,0.01, 3 mice
per group).
doi:10.1371/journal.pone.0006031.g003
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a therapeutic approach in humans.
The ability of adoptively transferred Tregs to suppress murine
lupus also raises a number of questions about how exogenously
expanded cells function to suppress disease that is not controlled
by the endogenous Treg population. We previously demonstrated
that B/W mice with active lupus have a significantly expanded
Treg population that is equal to or exceeds the population found in
non-autoimmune prone animals[24]. Yet it appears that this Treg
expansion is insufficient to control the proliferation and function of
autoreactive lymphocytes in lupus. One possible explanation for
this failure is that the Treg expansion is simply insufficient to
suppress the number of autoreactive lymphocytes that occur in
lupus. Another possibility is that the endogenous Tregs do not have
proper function in vivo. Our extensive in vitro evaluation of purified
B/W Tregs suggest that these cells do not have a defect in their
ability to suppress autologous T cell proliferation, however the true
functional capacity of these cells in vivo is not known. Importantly,
while the in vitro suppressive function of freshly isolated B/W Tregs
is equivalent to Tregs isolated from non-autoimmune prone BALB/
c mice, this function can nonetheless be significantly enhanced by
in vitro activation. Consistent with observations in other murine
Figure 4. In vivo survival and proliferation of expanded Tregs detected 30 days following adoptive transfer. A) A small population of
CFSE
+ labeled cells could be detected and FACS sorted at 30 days from a pool of lymphocyte isolation from lymphatic, splenic, salivary gland, lung,
liver and kidney tissue (FITC bright sort gate shown containing ,0.2% of CD4
+ T cells). B) Characteristic Foxp3 staining of sorted FITC bright cells
demonstrating .90% of these cells are Foxp3
+ (dark grey histogram), consistent with these cells being derived from the adoptively transferred CFSE
labeled, Foxp3
+Tregs and not FACS artifact (isotype control shown in light grey histogram, 3 mice cohort).
doi:10.1371/journal.pone.0006031.g004
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+ and CTLA-
4 expression. In addition, the expanded Tregs demonstrate
significantly enhanced in vivo survival as compared to freshly
isolated cells. These data suggest a basis for the efficacy of ex-vivo
expanded autologous Tregs in suppressing disease in lupus prone
mice. In some autoimmunity models the Teffs are resistant to Treg
suppression in vitro and/or in vivo[17,36]. For this study we
utilized Teff from 29-week-old mice that on average had developed
antinuclear antibodies and low titers of dsDNA antibodies, but had
not yet progressed to clinically active lupus. In this critical stage of
disease evolution we did not observe resistance of Teff cells to
CD4
+CD25
+ Treg mediated in vitro suppression. It is known that
Figure 5. CD4
+Foxp3
2Teff-conditioned demonstrate impaired in vivo survival and proliferation following adoptive transfer. At each time
point, an aliquot of CFSE labeled cells was fixed and stained with Pacific-Blue Foxp3 to permit measurement of the ratio Tregs and Teff-conditioned.A )
Baseline FITC-CFSE fluorescence of expanded CD4
+CD25
+ lymphocytes just prior to adoptive transfer. Foxp3 stain demonstrates this exogenous
expanded population containing 85% Foxp3
+Tregs and 15% Foxp3
2Teff-conditioined (contaminating Teff cells contained within the expanded Tregs
population) at the time of transfer. B–C) Dot plot and histogram of the FITC-CFSE fluorescent intensity of both Foxp3
+ Tregs and Foxp3
2 Teff-conditioned
cells recovered from lymphatic and solid organ tissue 4 days after adoptive transfer. Panels B–C demonstrate a significantly reduced survival and
proliferation of Teff-conditioned as compared to Tregs such that Teff-conditioned comprise ,3% of the recovered CFSE
+ population. Data reflects typical
finding from 6 separate experiments.
doi:10.1371/journal.pone.0006031.g005
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to achieve a suppressor phenotype. It is thus possible that the in
vitro suppression assay is insensitive to a heterogeneous Treg
activation state due to the dominant suppression capacity of those
Tregs that have already become activated. The enhanced in vitro
and likely in vivo function of Tregs we observe following in vitro
activation likely reflects at least in part the suppressive function of
a more homogenously activated Treg population. Additional
studies will be required to better characterize the factors
responsible for the enhanced suppressor capacity of these
expanded cells. In this study we did not attempt to compare
disease suppression by supplementation of freshly isolated Tregs
based on several observations. The protocol to isolate highly
enriched Tregs results in a total recovery of fresh Tregs from each
donor mouse of only 400,000 to 800,000 per mouse and it would
therefore require an impractical average of 8 donor mice for each
treatment mouse tested. In addition, the in vivo survival of freshly
isolated, CFSE labeled Tregs demonstrated these cells had very
poor survival relative to expanded cells decreasing the potential
biologic impact of transferred freshly isolated cells.
Despite inhibition of lupus nephritis and prolonged survival, the
majority of mice receiving Treg transfer progressed to active
disease during long-term follow-up. This pattern of inhibiting
disease onset, but not the final disease severity with a single
adoptive transfer is similar to the benefit observed when a more
restricted population of CD4
+CD25
+CD62L
HI Tregs was adop-
tively transferred. While not compared directly in a single
treatment study, no significant differences in either the size or
duration of the treatment response is evident between mice
receiving equal numbers of expanded CD4
+CD25
+CD62L
HI or
CD4
+CD25
+ Tregs. Future studies utilizing more sensitive
biomarkers of disease activity than proteinuria, antibody forma-
Figure 6. Persistent in vivo survival and proliferation of CD4
+Foxp3
2 Teffs when these cells are first expanded in vitro under Treg
depleted culture conditions (expanded, ‘‘unconditioned’’ Teffs). A) Survival and division of CFSE labeled, unconditioned CD4
+Foxp3
2 Teffs
could be detected up to 17 days following adoptive transfer at which time the FITC intensity of CFSE labeled cells approached the auto-fluorescent
baseline. Dot plot at day 17 demonstrating the sorting gate for FITC-bright, CFSE
+ cells. B) Cells sorted from the gate in Panel A are .98% Foxp3
2
consistent with the adoptively transferred Teffs (characteristic findings from 3 mice).
doi:10.1371/journal.pone.0006031.g006
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PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e6031Figure 7. In vivo survival and proliferation of expanded Tregs and Teffs (independently injected into the same mouse) indicating
impaired survival of Teff-conditioned is not intrinsic to all transferred Teffs, but instead due to co-culture with Tregs. A) CFSE
+ and SNARF-1
cells recovered four days following independent injections of expanded CFSE
+ CD4
+CD25
+ cells (containing Tregs and Teff-conditioned) and expanded
SNARF-1
+ CD4
+CD25
2 Teffs (unconditioned Teffs) demonstrating approximately equal survival of both populations (,0.4% of recovered lymphocytes
each). The ratio of injected cells on Day 0 was 45% Tregs, 10% Teff-conditioned, 45% unconditioned Teffs. B) Histogram of recovered CFSE
+ and SNARF-1
+
cells at day 4 demonstrate persistence of ‘‘unconditioned’’ Teffs (SNARF-1
+ cells) equivalent to survival of the CFSE
+Treg/Teff-conditioned mix, a finding not
observed when only Tregs and Teff-conditioned are co-transferred (as shown in Figure 5). C–D) Foxp3 analysis of sorted cells demonstrating that surviving
CFSE
+ cells are Tregs (97% Foxp3
+) and SNARF-1
+ cells are ‘‘unconditioned’’ Teffs (Foxp3
2), indicating impaired survival and proliferation of transferred
Teff-conditioned is a consequence of co-culture with Treg during exogenous expansion (characteristic findings from 5 mice).
doi:10.1371/journal.pone.0006031.g007
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Treg subsets in disease suppression. Multiple factors may
contribute to the duration of therapeutic benefit of a single
adoptive transfer. Limitations on the ability to track adoptively
transferred Tregs in our B/W mice leave unresolved the question of
how long transferred cells survive and continue to exert a
suppressor phenotype. Due to their wide distribution to both
lymphatics and solid organ tissue, it is not possible to specify the
exact number of surviving cells at a given time point following
Figure 8. Inhibition of proteinuria in Treg treated mice. Mice
receiving adoptively transferred Tregs had significantly reduced progres-
sion to proteinuria $100 mg/dl over the 12 weeks following transfer as
compared to either PBS or CD4
+CD25
2 T cell control groups (p#0.025
starting week 8, n=22 for Treg and Teff groups, n=21 for PBS group).
doi:10.1371/journal.pone.0006031.g008
Figure 9. Inhibition of immune complex renal damage in Treg treated mice. Typical kidney sections demonstrating less severe IgG and IgM
deposition in mice receiving adoptive Treg transfer (Figure 6A–B respectively) as compared to mice receiving either control therapy (Teff control
mouse, Figure 6C–D).
doi:10.1371/journal.pone.0006031.g009
Figure 10. Prolonged survival in Treg treated mice. Mice receiving
adoptive transfer of Tregs had significantly prolonged survival first
evident 9 weeks after transfer (p,0.05 at week 9) as compared to either
control group.
doi:10.1371/journal.pone.0006031.g010
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surviving and proliferating to 30 days, but the absolute number
of recovered cells is small and may reflect a diminishing survival
with time. From our sampling of major lymph nodes, spleen, and
solid organs we estimate that ,10% of cells persist 5–7 days post
transfer, ,1–3% persist 14 days post transfer, and ,1%
demonstrate long term survival to our detection threshold of 30
days. Whether the delay in disease onset is due to transient non-
specific bystander suppression effect from the large number of
activated Tregs transferred or from the smaller number of long
lived, potentially antigen specific Tregs is unclear. While further
studies will be required to expand the understanding of both the
mechanisms of action and therapeutic potential of adoptively
transferred Tregs in the treatment of SLE, this study supports the
potential benefits of augmenting Treg number or function as a
novel therapeutic approach to the treatment of this disease.
In conclusion, our results demonstrate that exogenous expan-
sion and adoptive transfer of the regulatory T cell subset defined
by CD4 and CD25 expression produces a population of highly
suppressive, long-lived Tregs capable of delaying the onset of
glomerulonephritis in a murine model of lupus. Co-culture and
adoptive transfer of a small population of contaminating,
potentially autoreactive Teffs does not exacerbate autoimmune
disease or limit the potential of Tregs to suppress disease, in part
due to the short in vivo survival time and anergic phenotype of
these co-cultured cells.
Supporting Information
Dataset S1 Proteinuria and Survival Data. Serial proteinuria
and survival in treatment and control mice. Mice received
CD4
+CD25
+Tregs, CD4
+CD25
2Teffectors control cells, or PBS.
Proteinuria score is recorded as 0–4 as measured by urine dipstick.
Mouse deaths noted by X marks.
Found at: doi:10.1371/journal.pone.0006031.s001 (0.04 MB
XLS)
Dataset S2 Serial proteinuria in renal histology mice. Mice were
sacrificed 8-weeks after adoptive transfer of CD4
+CD25
+Tregs or
PBS. Proteinuria score is recorded as 0–4 as measured by urine
dipstick.
Found at: doi:10.1371/journal.pone.0006031.s002 (0.02 MB
XLS)
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